| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/23/2005 | US6933281 Administering nonapeptides conjugated to drugs or labels, that preferentially targets the lungs, pancreas, skins, eyes, prostate galnds , ovaries, adrenal gland, liver or alimentary canal; drug delivery; medical diagnosis |
| 08/23/2005 | US6933271 Aimed at neoplastic cells with gonadotropin releasing hormone binding sites; anticarcinogenic agents; genetically engineered Pseudomonas Exotoxin |
| 08/23/2005 | US6933116 Nucleic acid ligand binding site identification |
| 08/23/2005 | US6933114 Nucleotide sequence ligand for use in the detection diagnosis and treatment of cancer |
| 08/23/2005 | US6932984 Method of microencapsulation |
| 08/23/2005 | US6932971 Nicotine-hapten composition for diagnosing, preventing and treating drug addiction; vaccine for treating nicotine addiction, palliating nicotine withdrawal, facilitating smoking cessation and/or preventing relapse |
| 08/23/2005 | US6932964 Cosmetic composition with water-soluble or water-dispersible polymers |
| 08/23/2005 | US6932962 for use in pressurized metered dose inhalers (pMDI's); surfactants such as decyl glucoside or dodecyl maltoside |
| 08/23/2005 | US6932861 Edible PGA coating composition |
| 08/23/2005 | CA2310585C Novel administration form comprising an acid-labile active compound |
| 08/23/2005 | CA2265116C Structured water in cosmetic compositions |
| 08/23/2005 | CA2218714C Dosage form comprising oxybutynin |
| 08/23/2005 | CA2187898C Controlled release biodegradable microspheres and method of preparation |
| 08/19/2005 | CA2458026A1 Antifungal and/or antimycotic external preparation for nail |
| 08/18/2005 | WO2005075992A1 Mct1 transporter expressed in blood brain barrier cells |
| 08/18/2005 | WO2005075647A1 Humanized antibody |
| 08/18/2005 | WO2005075021A2 Chemically-modified human growth hormone receptor antagonist conjugates |
| 08/18/2005 | WO2005074994A1 Oat3 transporter expressed in blood brain barrier cells |
| 08/18/2005 | WO2005074993A2 Method for producing conjugates of polysaccharides and polynucleotides |
| 08/18/2005 | WO2005074992A1 Pharmaceutical form of reduced toxicity for oral administration of indomethacin |
| 08/18/2005 | WO2005074991A1 Antitumor agent |
| 08/18/2005 | WO2005074977A1 Paraoxonase-containing pharmaceutical preparation |
| 08/18/2005 | WO2005074976A1 Composition comprising polymeric material and uses thereof |
| 08/18/2005 | WO2005074949A1 Treatment of ungual and subungual diseases with antimicrobial metal compositions |
| 08/18/2005 | WO2005074937A1 Oral cyclodextrin complexes of anti-tuberculosis drug |
| 08/18/2005 | WO2005074936A1 Aqueous solution containing pyrazoloacridone derivative |
| 08/18/2005 | WO2005074914A1 Anthelmintic composition |
| 08/18/2005 | WO2005074912A2 Antiparasitic composition containing an organic amine salt of closantel |
| 08/18/2005 | WO2005074901A2 New effector conjugates, process for their production and their pharmaceutical use |
| 08/18/2005 | WO2005074897A2 Formulation auxiliary agents (aminopropanoic acid derivative) in cosmetic or dermatological preparations |
| 08/18/2005 | WO2005074896A1 Sustained release preparation |
| 08/18/2005 | WO2005074892A1 The cream containing interferon liposome |
| 08/18/2005 | WO2005074891A1 Microemulsion formulations comprising particular substance p antagonists |
| 08/18/2005 | WO2005074890A1 Semisolid matrix pharmaceutical formulations |
| 08/18/2005 | WO2005074889A1 Novel compositions of taxol derivatives and the process for the manufacture thereof |
| 08/18/2005 | WO2005074888A2 Replacement enzyme cochleates |
| 08/18/2005 | WO2005074887A2 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |
| 08/18/2005 | WO2005074885A1 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
| 08/18/2005 | WO2005074883A1 Aqueous compositions containing mixtures of synthetic polymers and biopolymers, useful in the treatment of skin and mucosal tissues dryness, and suitable as vehicles of active ingredients |
| 08/18/2005 | WO2005074835A1 Hydrophilic matrix for delivery of active agent and product containing same |
| 08/18/2005 | WO2005074650A2 Modified human four helical bundle polypeptides and their uses |
| 08/18/2005 | WO2005074546A2 Modified human growth hormone polypeptides and their uses |
| 08/18/2005 | WO2005074524A2 Modified human interferon polypeptides and their uses |
| 08/18/2005 | WO2005074460A2 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods |
| 08/18/2005 | WO2005045041A3 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina) |
| 08/18/2005 | WO2005035003A3 Compositions and methods for increasing drug efficiency |
| 08/18/2005 | WO2005032513A3 Pantoprazole multiparticulate formulations |
| 08/18/2005 | WO2005027841A3 Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease |
| 08/18/2005 | WO2005026318A3 Methods and compositions for producing antigenic responses |
| 08/18/2005 | WO2005007854A3 Polycationic compositions for cellular delivery of polynucleotides |
| 08/18/2005 | WO2004091527A3 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films |
| 08/18/2005 | WO2004066946A3 Method for evaluating the efficacy of certain cancer treatments |
| 08/18/2005 | US20050182236 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation |
| 08/18/2005 | US20050182142 1,2-alkanediol, and citral, geraniol, nerol, perillaldehyde, alpha -terpineol, dodecanol and/or L-carvone |
| 08/18/2005 | US20050182124 Ester bacteriostat for stabilizing cosmetics |
| 08/18/2005 | US20050182103 Substituted 2,3-diphenyl pyridines |
| 08/18/2005 | US20050182039 Use of Loteprednol etabonate for the treatment of dry eye |
| 08/18/2005 | US20050182030 Antitumor, anticancer agents; osteoporosis; bone disorders; Paget's disorders; solution is provided in a sealed non-reactive plastic container of polypropylene, ABS, polyethylene, PVC, polycycloolefin; injectable, sterile, ready to use, pyrogen-free solution |
| 08/18/2005 | US20050182029 Metformin tocopherol phosphate gel; time-release agent; antihyperglycemic agent; improved gastrointestinal absorption |
| 08/18/2005 | US20050182026 Dioleyl phosphatidylcholine (DOPC); distearyl phosphatidylcholine (DSPC) and dipalmitoyl phosphatidylcholine (DPPC) as surface active phosphotidyls; phosphatidyl glycerol, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, or chlorestyl palmitate as spreading agent |
| 08/18/2005 | US20050182024 Estrogen complexes for ovulation inhibition; storage stability; 85% w/w in relation to the initial content of said estrogen after storage for 12 months at 40 degrees C. and 75% relative humidity |
| 08/18/2005 | US20050182023 Process to prepare semicarbazones' and/or tiosemicarbazones' formulations using cyclodextrins and their derivatives and products obtained by this process |
| 08/18/2005 | US20050182019 Phosphonate compounds |
| 08/18/2005 | US20050182017 Immunostimulatory nucleic acid molecules |
| 08/18/2005 | US20050182009 siNA molecule comprising a double-stranded structure that down-regulates expression of NF-Kappa B / REL-A , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 08/18/2005 | US20050182008 chemically synthesized double stranded siNA; NOGO genes encode potent inhibitors of neurite outgrowth; treating various nervous system disorders such as brain or spinal cord injury, cerebrovascular disorders, Alzheimer's disease, dementia, and neurodegenerative disorders |
| 08/18/2005 | US20050182007 siNA molecule comprising a double-stranded structure that down-regulates expression of interleukin and interleukin receptor , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 08/18/2005 | US20050182006 Cancer and proliferative diseases |
| 08/18/2005 | US20050181999 Comprising a biologically active agent (e.g., antifungal) , urea and an acid (lactic acid) or ethoxydiglycol; provide better bioavailability of the active agent within the nail |
| 08/18/2005 | US20050181996 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 08/18/2005 | US20050181989 Selective substrates for matrix metalloproteinases |
| 08/18/2005 | US20050181985 Coupling proteins to a modified polysaccharide |
| 08/18/2005 | US20050181976 coupled to therapeutic proteins or peptides; biochemical conjugation |
| 08/18/2005 | US20050181475 Immunoglobulin which comprises at least two different epitopes of a tumor-associated antigen for use as diagnostic and therapeutic tool in detection, treatment and prevention of cell proliferative disorders; immunotherapy |
| 08/18/2005 | US20050181474 Transport peptides and uses therefor |
| 08/18/2005 | US20050181448 Biological products |
| 08/18/2005 | US20050181358 Soluble complex comprising a retroviral surface glycoprotein |
| 08/18/2005 | US20050181063 Biologically active agent being encapsulated within microspheres which comprise a polymer which has a molecular weight in excess of 94 kDa and a maximum diameter of 20 mu m; for the intra-nasal administration of vaccines in a single shot vaccination |
| 08/18/2005 | US20050181054 comprising a water-insoluble and/or water-low soluble substance, a medicament, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm; efficient penetration and high permeability blood at the mucosa |
| 08/18/2005 | US20050181053 Comprises methacrylic acid-methyl methacrylate copolymer layers for drug delivery to gastrointestinal tract ; solid unit dosage form for oral administration; improved resistance to coating fractures |
| 08/18/2005 | US20050181050 Dosage forms using drug-loaded ion exchange resins |
| 08/18/2005 | US20050181046 Tamper-resistant oral opioid agonist formulations |
| 08/18/2005 | US20050181045 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 08/18/2005 | US20050181042 Composition for oral or rectal administration |
| 08/18/2005 | US20050181039 Micelles |
| 08/18/2005 | US20050181038 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 08/18/2005 | US20050181031 Permeation enhancer comprising fatty acid ester and/or a terpene; urogenital and respiratory system disorders |
| 08/18/2005 | US20050181028 Topical composition and method for treating occlusive wounds |
| 08/18/2005 | US20050181017 Compositions and methods for localized therapy of the eye |
| 08/18/2005 | US20050180997 Combination product comprising a positive oil in water emulsion with compound presenting free NH2 groups at the oil-water interface, and an antibody, wherein compound is linked to antibody by heterobifunctional linker, linking NH2 groups to SH groups on the antibody hinge region |
| 08/18/2005 | US20050180972 high potency and/or are capable of promoting accumulation of the anti-CD20 ADC into CD20-expressing cells; pharmaceutical compositions and kits |
| 08/18/2005 | US20050180965 Heat-reversible composition treating hyposalia and asialia |
| 08/18/2005 | US20050180960 producer cell (encapsulated in a matrix containing immunostimulating alginates) expresses a molecule that is an inhibitor of the growth of a CNS tumor |
| 08/18/2005 | US20050180955 gene therapy; delivering recombinant adeno-associated virus virions to the brain; pumping; transgene encodes an aromatic amino acid decarboxylase |
| 08/18/2005 | US20050180950 Chemically modified TNF-alpha |
| 08/18/2005 | US20050180946 such as triethanolamine with 2 hydroxyethyl groups derivatized with polyethylene glycol, and the amine group conjugated to drugs such as antitumor agent interferon |
| 08/18/2005 | US20050180924 Composition and method for moisturizing nasal tissue |
| 08/18/2005 | DE102004001558A1 Arzneimittel zur topischen Applikation bei Tieren Drugs for topical application in animals |
| 08/18/2005 | CA2555306A1 Humanized antibody |
| 08/18/2005 | CA2555033A1 Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof |